TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following inclusion criteria include, but are not limited to:~1. Adults ≥ 18 years of age with foveal center-involved macular edema (ME) secondary to BRVO diagnosed within 12 months before the screening visit~2. ETDRS BCVA: letter score of 73 to 24 (20/40 to 20/320) in the study eye at screening and at day 1~3. Provide signed informed consent~Exclusion Criteria:~The following exclusion criteria include, but are not limited to:~1. Current bilateral manifestation of BRVO~2. Uncontrolled glaucoma defined as ≥ 25 mmHg on optimal medical regimen, or previous filtration surgery in either the study eye or the fellow eye~3. Insufficient clearing of macular hemorrhage that would prevent the patient from receiving laser treatment safely on day 1 (patients that meet this criterion may be rescreened once the macular hemorrhage resolves)~4. Uncontrolled diabetes mellitus (DM)~5. Previous use of intraocular corticosteroids or anti-angiogenic drugs in the study eye~6. Use of periocular corticosteroids in the study eye within 3 months before day 1~7. Use of intraocular or periocular corticosteroids or anti-angiogenic drugs in the fellow eye within 3 months before day 1~8. Previous administration of systemic anti-angiogenic medications~9. Panretinal scatter photocoagulation, sector laser photocoagulation, or macular grid photocoagulation in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macular Laser Photocoagulation Treatment (Control) (Type: SHAM_COMPARATOR): Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
- Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 (Type: EXPERIMENTAL): Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Argon Plasma Coagulation for Barrett's Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive adult patients with low-grade dysplasia in flat Barrett's mucosa referred for endoscopic treatment,~* signed an informed consent to participate in the study.~Exclusion Criteria:~* high-grade dysplasia or adenocarcinoma,~* visible lesions (nodules, ulcerations) in Barrett's mucosa,~* serious comorbidities and short life expectancy,~* coagulopathy,~* pregnancy or lactation,~* psychiatric disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APC 90W / PPI 120mg (Type: EXPERIMENTAL): treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
- APC 90W / PPI 40mg (Type: ACTIVE_COMPARATOR): treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
- APC 60 W/ PPI 120mg (Type: ACTIVE_COMPARATOR): treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 / 48 wk Pivotal PFT vs PBO in COPD II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* All patients must have a diagnosis of chronic obstructive pulmonary disease~* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 \<80% predicted and post-bronchodilator FEV1/FVC \<70%~Exclusion criteria:~* Patients with a significant disease other than COPD~* Patients with a history of asthma~* Patients with any of the following conditions:~a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).~* Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).~* Has participated in a clinical study in which febuxostat was administered.~* Is completing Phase 3 Studies C02-009 or C02-010.~* Must not have experienced any serious study drug-related adverse events in the previous study.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study~Exclusion Criteria:~* Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.~* Is intolerant of allopurinol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Allopurinol QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* OAM-naïve or have been taking OAM monotherapy for at least 3 months~* Glycosylated Hemoglobin (HbA1c) value of ≥7.0% to ≤10.5% for OAM-naïve participants or ≥6.5% to ≤10.0% for participants taking OAM monotherapy~* Adult men or adult non-pregnant, non-breastfeeding women~* Stable weight (±5%) ≥3 months prior to screening~* Body mass index (BMI) of ≥19.0 to ≤35.0 kilograms per square meter (kg/m\^2)~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have previously been treated with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic during the 3 months before screening~* Are currently taking dipeptidylpeptidase-IV (DPP-IV) inhibitor and thiazolidinediones (TZD) during the 3 months before screening~* Have gastric emptying abnormality~* Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke~* Have poorly controlled hypertension (systolic blood pressure above 160 millimeters of mercury \[mmHg\] or diastolic blood pressure above 95 mmHg)~* Have impaired liver function~* Have impaired kidney function~* Have history of chronic pancreatitis or acute pancreatitis~* Have a serum calcitonin ≥20 picogram/milliliter (pg/mL)~* Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma or multiple endocrine neoplasia type 2 (MEN 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): 1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
- 0.75 mg Dulaglutide (Type: EXPERIMENTAL): 0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): 1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Filgrastim in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* People with probable AD (by NINDS/ADRDA criteria) who are likely to be testable at the conclusion of the study period, and who do not have concurrent medical conditions or medications that might influence cognitive testing or that would increase the risk of treatment~* The participants will have a Min Mental State Examination score of between 10 and 24~* stable medical condition and stable medications for 3 months prior to screening~* study partner (spouse or caregiver) to accompany patient to all scheduled visits; able to complete baseline assessments~* physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests~Exclusion Criteria:~* clinically significant cardiac arrhythmia~* history of clinically significant stroke~* use of another investigational drug within 2 months of screening~* current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder alcohol or substance abuse; residence in a skilled nursing facility (but patients in assisted living facility are acceptable)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- G-CSF (filgrastim) first phase (Type: EXPERIMENTAL): Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
- Placebo first phase (Type: PLACEBO_COMPARATOR): Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years.~* Physician diagnosis of asthma.~* FEV1 60-80% predicted during the day.~* FEV1 increases ≥ 12 % and to ≥ 80% predicted after 2- 4 puffs of albuterol HFA MDI delivered by antistatic VHC.~* No smoking in the previous year and \< 10-pack year history.~* No history of severe asthma attacks requiring ER visit or hospitalization in the previous three months.~Exclusion Criteria:~* Patient required a short course of oral steroid in the past 30 days.~* Any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications.~* History of viral respiratory tract infection in the 3 weeks prior to the screening visit.~* Positive pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Anti-static then Static for Albuterol (Type: EXPERIMENTAL): albuterol anti-static first then static chamber second.
- Static then Anti-static for Albuterol (Type: EXPERIMENTAL): static then antistatic albuterol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ \[height (m)\]²~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45~Exclusion Criteria:~* WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Current smoker or recent (within 1 month) history of regular tobacco use~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Abnormal urinalysis at screening~* Glucosuria at screening~* Abnormal liver functions tests (ALT, AST or total bilirubin \> 10 % ULN)~* Presence of edema on physical exam~* History of diabetes mellitus~* History of heart failure~* History of renal insufficiency~* History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months~* Positive urine screen for drugs of abuse either at screening or before dosing~* Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody~* History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)~* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)~* Prior exposure to dapagliflozin within 3 months of Day -1~* Exposure to any investigational drug or placebo within 4 weeks of Day -1~* Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration~* Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration~* Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Bumetanide (Type: ACTIVE_COMPARATOR): None
- Dapagliflozin (Type: ACTIVE_COMPARATOR): None
- Bumetanide + Dapagliflozin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. OSA patients (AHI \> 10 events/h), and~2. normal nasal resistance measured in seated and supine position with active anterior and posterior rhinomanometry (\< 3.0 cmH20•L-1•s).~Exclusion Criteria:~1. recent surgery involving the upper airways,~2. central apnoeas more than three per hour or five percent of total apnoeas,~3. total sleep time during polysomnographies less than three hours,~4. current treatment with nasal decongestants and topical steroids, and~5. upper or lower respiratory tract disease, including a history of nasal allergy, and~6. smoking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- nasal spray with tramazoline and dexamethazone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effect of Doxycycline in Patients With Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Biopsy-proven amyloidosis~* Biochemical or clinical evidence of amyloid induced end-organ dysfunction~Exclusion Criteria:~* Concurrent use of other tetracyclines~* Ongoing active treatment for amyloidosis~* Pregnancy or unwillingness to use contraception by women of childbearing age~* Doxycycline drug allergy/hypersensitivity~* ECOG performance status \> 3~* NYHA class \> 3~* Renal insufficiency (estimated creatinine clearance \< 25 ml/min)~* Transaminitis (AST or ALT \> 5 times upper limit of normal)~* Diabetes mellitus or hemoglobin A1C \> 6.2%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- doxycycline 100 mg po bid x 12 months (Type: EXPERIMENTAL): Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Canadian Hemophilia Prophylaxis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (factor level less than 2%).~* Age greater than 1 year and less than or equal to 2.5 years.~* Normal joints using the World Federation of Hemophilia orthopedic scale.~* Normal radiographs of joints in which bleeding has occurred using the World Federation of Hemophilia radiographic scale.~* Platelet count of \> 150,000.~* Informed consent to participate.~Exclusion Criteria:~* Three or more clinically determined bleeds into any single elbow, knee or ankle.~* Presence or past history of a circulating inhibitor (level ≥ 0.5 Bethesda Units).~* Family judged to be non-compliant by the local hemophilia clinic director.~* Competing risk (symptomatic HIV infection, juvenile rheumatoid arthritis, metabolic bone disease, or other diseases known to cause or mimic arthritis.)

- Gender: MALE
- Minimum Age: 12 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- Factor VIII (Type: EXPERIMENTAL): escalating dose Factor VIII

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete